Learning Objectives
1. Review and apply national guideline treatment strategies to the following gastrointestinal (GI) disorders: gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), ulcerative colitis (UC), Crohn disease (CD), viral hepatitis, chronic liver disease, constipation, diarrhea, irritable bowel syndrome (IBS), nausea, vomiting, pancreatitis, and upper GI bleeding, including prevention of stress-related mucosal disease (SRMD). 2. Recommend appropriate pharmacologic and nonpharmacologic interventions for the management of GERD. 3. Differentiate between clinical signs, symptoms, risk factors, and treatment of PUD associated with both Helicobacter pylori and nonsteroidal antiinflammatory drugs. 4. Discuss the role of pharmacologic intervention in the treatment of nonvariceal upper GI bleeding and the prevention of SRMD. 5. Review the clinical differences in signs, symptoms, and treatment of CD and UC. 6. Identify the common manifestations of chronic liver disease and their treatment. 7. Review the treatment and prevention of both acute and chronic viral hepatitis. 8. Recognize pertinent information for educating patients and prescribers about the appropriate use of pharmacologic agents for various GI disorders. 9. Recommend appropriate pharmacologic and nonpharmacologic interventions for diarrhea and constipation. 10. Review recommendations for the treatment and prevention of nausea and vomiting. 11. Discuss the clinical and treatment differences between acute and chronic pancreatitis. 12. Discuss the role of pharmacologic intervention in the treatment of IBS. 13. Discuss commonly encountered statistical tests and concepts, using GI disorders as examples.
Self-Assessment Questions
Answers and explanations to these questions can be found at the end of the chapter. A. Sulfasalazine 4 g/day.
B. Hydrocortisone enema 100 mg every night.
C. 6-mercaptopurine (6-MP) 75 mg/day.
D. Mesalamine (Delzicol) 1.6 g orally three times/day.
5.
A 45-year-old African American man with a history of alcoholic cirrhosis (Child-Pugh class B) was seen in the clinic today for a follow-up. He was recently referred for screening endoscopy, which revealed several large esophageal varices. He has no history of bleeding; 1 month ago, propranolol 10 mg orally three times/day was initiated. A. Sodium phosphate oral solution.
B. Bisacodyl suppository.
C. Methylcellulose tablets.
D. Methylnaltrexone injection.
13. A 65-year-old man with a history of hypothyroidism, heart failure, and MI is admitted to the intensive care unit with severe community-acquired pneumonia. Six hours after admission, he develops acute respiratory failure, hypotension, and acute kidney injury from presumed sepsis; he is placed on mechanical ventilation. An NG tube is placed. He currently takes ramipril 10 mg/day, metoprolol 100 mg twice daily, levothyroxine 125 mcg/day, and aspirin 81 mg/day. His WBC is 25 × 10 3 cells/ mm 3 , platelet count 170,000/mm 3 , SCr 3.8 mg/dL (baseline 1.1 mg/dL), potassium 4.9 mEq/L, BUN 65 mg/dL, international normalized ratio (INR) 1.1, AST 30 IU/mL, and ALT 45 IU/mL. He is 68 inches tall and weighs 79 kg. Which approach is most appropriate for preventing stress-related mucosal disease (SRMD) in this patient?
A. Sucralfate 1 g four times/day by NG tube.
B. Magnesium hydroxide 30 mL four times/day by NG tube.
C. Cimetidine 8-mg/hour intravenous infusion.
D. Pantoprazole 40 mg intravenously once daily.
14. A newly available NSAID was designed to reduce the incidence of adverse GI events compared with traditional NSAIDs. A large retrospective cohort study compares the incidence of ulceration and bleeding associated with the use of this new NSAID with that of ibuprofen and naproxen. The results indicate that the new agent is associated with no statistically or clinically significant reduction in ulceration or bleeding with long-term use compared with ibuprofen and naproxen. The investigators of the study argue that the lack of difference in safety is because the drug is being promoted as safer; therefore, most patients receiving it are at a much higher baseline risk of NSAID-induced ulceration and bleeding. If this phenomenon did indeed affect the study results, which potential source of bias would probably be present?
A. Recall bias.
B. Misclassification bias.
C. Interviewer bias.
D. Channeling bias.
15. A new enzyme immunoassay for HCV RNA has a reported sensitivity of 95% and a specificity of 92%. If the prevalence of HCV in a cohort of 500 patients is 40%, which best represents the positive predictive value of this new test?
A. 75%.
B. 89%.
C. 92%.
D. 96%.
I. GASTROESOPHAGEAL REFLUX DISEASE (GERD)
A. Definition 1. "GERD is defined by consensus and as such is a disease comprising symptoms, end-organ effects and complications related to the reflux of gastric contents into the esophagus, oral cavity, and/or the lung"
Strength of guideline evidence is rated by the GRADE system (Level of Evidence and Strength). Low) e. Avoid tight-fitting clothing (decreases intra-abdominal pressure). f. Avoid medications that may reduce LES pressure, delay gastric emptying, or cause direct irritation: α-adrenergic antagonists, anticholinergics, benzodiazepines, calcium channel blockers, estrogen, nitrates, opiates, tricyclic antidepressants, theophylline, NSAIDs, and aspirin. 2. Pharmacologic therapies a. Initial treatment depends on the severity, frequency, and duration of symptoms. i. "
Step-down" treatment: Starting with maximal therapy, such as therapeutic doses of PPIs, is always appropriate as a first-line strategy in patients with documented esophageal erosion. Advantages: Rapid symptom relief, avoidance of overinvestigation. Disadvantages: Potential overtreatment, higher drug cost, increased potential for adverse effects ii. "
Step-up" treatment: Start with lower-dose over-the-counter (OTC) products. Advantages:
Avoids overtreatment, has lower initial drug cost. Disadvantages: Potential undertreatment (partial symptom relief; may take longer for symptom control; may lead to overinvestigation) b. The AGA treatment guideline recommendation summary follows.
